We are international

Myeloma Minute
January 8, 2015
January 8, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF



This week's question: What’s new with the Black Swan Research Initiative®?


Multiple Myeloma Bone Study



 Upcoming Events

Thursday, January 15, 2015
IMF Teleconference:
Best of ASH 2014:
What Patients & Caregivers Need to Know
7pm ET / 4 pm PT


Watch the IMF Mambo for Myeloma & Support This Challenge




Is a Cancer Diagnosis Just a Matter of Bad Luck?


A mathematical analysis of cancer statistics recently published in the journal Science is generating a lot of attention. The study suggests that many cases of cancer may be the result of random cell mutations or bad biological luck, rather than genetics, behavior, or environmental factors. The research here could lead some to argue that cancer can’t be prevented. But might that attitude be dangerous? IMF Chairman Dr. Brian Durie weighs in with a new blog post on what all of this means, which you can READ HERE.


Selinexor Receives Orphan Drug Designation from the FDA for Myeloma Treatment


There is good news today for myeloma patients as the US Food and Drug Administration (FDA) has granted orphan drug designation to selinexor for the treatment of myeloma. Selinexor is an oral drug from Karyopharm Therapeutics that is currently being evaluated in clinical trials. The FDA grants orphan drug designation to encourage companies to develop drugs that have the potential to treat conditions affecting 200,000 or fewer US patients annually. Advantages include an accelerated FDA review process. CLICK HERE for more on the orphan drug designation. CLICK HERE to learn more about selinexor from Dr. Brian Durie in #AskDrDurie.


Register for "Best of ASH 2014: What Patients & Caregivers Need To Know" Teleconference


Join Dr. Brian Durie for the IMF’s first teleconference of the new year: “Best of ASH 2014: What Patients & Caregivers Need to Know.” Taking place on Thursday, January 15, 2015 at 7 pm ET / 4 pm PT, the call will cover everything from the role of imaging, to new therapies and maintenance, to how the Affordable Care Act may affect your myeloma treatment. Be sure to have your questions ready for Dr. Durie because the 90-minute call will be interactive. CLICK HERE to register for this teleconference.


Oral Parity Advocates Needed!


Are you a myeloma patient living in Mississippi, New Hampshire, North Carolina, North Dakota, Pennsylvania, South Dakota, or West Virginia? The IMF Advocacy Team has active oral parity campaigns in your state to help provide access to affordable anti-cancer medications for you—and you can help! We are looking for advocates who are willing to share their stories and speak with in-state legislators to help get their support on this critical issue. If you are interested, please contact a member of the advocacy team at advocacy@myeloma.org or CLICK HERE for more details.


First 2015 IMF Patient & Family Seminar Set for Boca Raton


Our first Patient & Family Seminar of the new year is returning to Boca Raton, Florida from February 13 to February 14, 2015. The two-day event will see Drs. Brian Durie (IMF), Ola Landgren (Memorial Sloan Kettering Cancer Center), Ken Anderson (Dana-Farber Cancer Institute), Sagar Lonial (Winship Cancer Institute), and James Hoffman (Sylvester Comprehensive Cancer Center) delivering presentations on hot myeloma topics including managing side effects, handling psychosocial issues, best therapies for elderly patients and patients with transplant, clinical trials and new drugs, and more. CLICK HERE for more information and/or to register.

Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe

 related articles